Search Results
179 Results Found for “melanoma”
An immunosuppressed person is one whose immune function is impaired by underlying disease and/or immunosuppressive medications, resulting in reduced immunosurveillance against malignant cells and increased vulnerability to opportunistic infections. Longstanding immunosuppression has been linked to increased risk for cutaneous (...
Immune checkpoint inhibitors (ICIs) act by blocking inhibitory pathways such as programmed cell death protein 1 (PD-1), programmed cell death ligand 1 (PD-L1)Â and cytotoxic T lymphocyte-associated antigen 4Â (CTLA-4), thereby restoring T-cell activity and promoting tumour cell destruction.1,2Â The ability of tumours ...
The intestinal microbiota, composed of approximately 1,000 species and over 100 trillion micro-organisms, plays a vital role in host physiology, including metabolism, barrier function and immune regulation.1 Disruption of this delicate host–microbiota balance – known as dysbiosis – has been implicated in the ...
The first half of 2025 has brought exciting developments in oncology, with groundbreaking research and real-world progress showcased at ASCO, EHA and many more leading conferences around the world. We asked five of our touchONCOLOGY Future Leaders 2025 to share what they believe has been most impactful so far this year – here’s what they told us.
Rare gynaecological cancers remain an underfunded and understudied group of diseases. Prof. Isabelle Ray-Coquard discusses the diagnostic and therapeutic gaps, barriers to clinical trial participation, and the importance of international cooperation to advance care for these patients. Promising developments include immunotherapy, targeted approaches, and data-driven personalized strategies.
We are delighted to present the latest edition of touchREVIEWS in Oncology & Haematology. This issue underscores the evolving landscape of cancer therapeutics, showcasing advances across a wide range of malignancies, from haematologic diseases to solid tumours, through novel mechanisms, ...
Dr Soo Park reflects on the profound impact of mentorship, emphasizing patience and the importance of finding one’s voice. She finds fulfillment in combining science and compassion to support her patients and draws ongoing inspiration from their milestones, viewing her work in oncology as both a privilege and a source of purpose.
Lung cancer is the second most common type of cancer worldwide and in the USA, with its incidence varying depending on geographic and socioeconomic factors.1–3 According to data from the Global Cancer Observatory: Cancer Incidence, Mortality and Prevalence (GLOBACAN) database, ...
Liquid biopsy: Initial concepts and application in solid tumours The US National Cancer Institute defines liquid biopsy (LB) as ‘a test done on a sample of blood to look for cancer cells from a tumour that are circulating in the ...
Cancer is a leading cause of death worldwide and represents a growing major public health problem. Every year on February 4, World Cancer Day serves as a global initiative to raise awareness, promote education, and drive action in the fight against ...
"While groundbreaking treatments are transformative, patients often remember the kindness and humanity of their oncologist more than the medicine they receive" Introducing our Future Leaders series, in this interview Dr Rodrigo Munhoz (Oncology Center – Hospital SÃrio-Libanês in Sã...
Highlights Immunotherapy, especially combinatory immunotherapy, has shown promise with prolonged survival for patients with advanced mesothelioma in the first-line setting (see the sections on ‘Systemic treatment and immunotherapy debut’ and ‘Randomized immunotherapy trials of mesothelioma’). Histology-based therapy is important to ...
The COVID-19 pandemic accelerated the development of mRNA technologies, most notably with the creation of mRNA vaccines targeting SARS-CoV-2. While these vaccines helped control the pandemic, their potential may extend beyond infectious diseases, with growing interest in their potential application ...
The NIAGARA trial evaluated the combination of durvalumab (D) with neoadjuvant chemotherapy (NAC) followed by radical cystectomy (RC) and adjuvant durvalumab in cisplatin-eligible patients with muscle-invasive bladder cancer (MIBC). A total of 1063 patients were randomized to either receive durvalumab + NAC + ...
The phase II RELATIVITY-104 trial assessed the combination of nivolumab (NIVO) and relatlimab (RELA), a LAG-3-blocking antibody, alongside chemotherapy (PDCT) as a first-line treatment for metastatic non-small cell lung cancer (NSCLC). In this randomized trial, patients receiving NIVO + RELA + ...
The field of immuno-oncology has provided novel therapeutic agents that have led to significant improvements in patient outcomes across many tumour types. There have also been great efforts to incorporate immunotherapy (IO) into the treatment paradigms of gastrointestinal (GI) cancers. ...
Log into your Touch Account
Keep track of your clinical interests and newsletter subscriptions.
Sign up with an Email
Or use a .
Register now for FREE access
Already registered? Login below.
